Related Experiment Video
Updated: Jan 28, 2026

Direct Drug Delivery to Kidney via the Renal Artery
Published on: April 17, 2021
Kidney Safety Assessment: Current Practices in Drug Development
Sean P Troth1, Frank Simutis2, Gary S Friedman3
1Merck Research Laboratories, Department of Safety Assessment and Laboratory Animal Resources, West Point, PA.
Abstract:
The kidney's role as a major route of metabolism and clearance of xenobiotics and its ability to concentrate the glomerular filtrate make it particularly vulnerable to drug-induced toxicity. Improving kidney safety is an active area of research and there is a need in early stages of drug development for strategies and model systems to reliably identify nephrotoxic compounds and sufficiently characterize mechanisms to support drug pipeline decision making. In later stages of drug development the value of sensitive translational biomarkers to monitor kidney toxicity across species in nonclinical and clinical settings is gaining realization. Various tools and strategies for kidney safety assessment have emerged over the past decade; however, there is currently no clear consensus on best practices for their use across different phases of drug development. Here, we provide perspective on the scope of this problem in drug development, and an overview of progress in the field of kidney safety including several informative case examples of kidney toxicity de-risking scenarios encountered in the pharmaceutical industry. The results of a survey of pharmaceutical companies conducted through the Innovation and Quality Drug Safety consortium provides additional insight into recent experiences with compound attrition and different de-risking approaches across the industry.
Insights
Identifying kidney toxicity early in drug development is crucial. This research reviews current strategies and industry practices for assessing and mitigating drug-induced kidney injury, aiming to improve drug safety.
Area of Science:
- Pharmacology and Toxicology
- Drug Development
- Renal Physiology
Background:
- The kidney is highly susceptible to drug-induced toxicity due to its metabolic and filtration functions.
- Early identification of nephrotoxic compounds is essential for successful drug development.
- Translational biomarkers for monitoring kidney toxicity are increasingly recognized in later drug development stages.
Purpose of the Study:
- To provide perspective on the challenges of kidney safety assessment in drug development.
- To review advancements in kidney safety strategies and model systems.
- To offer insights into industry practices for de-risking nephrotoxic compounds.
Main Methods:
- Literature review of kidney safety assessment tools and strategies.
- Analysis of case examples in pharmaceutical drug development.
- Presentation of survey results from the Innovation and Quality Drug Safety consortium on industry experiences.
Main Results:
- Despite progress, a consensus on best practices for kidney safety assessment across drug development phases is lacking.
- Industry survey reveals diverse approaches to compound attrition and de-risking.
- Case examples illustrate successful de-risking scenarios for kidney toxicity.
Conclusions:
- There is a critical need for standardized and reliable methods for early kidney safety evaluation.
- Further research and collaboration are needed to establish best practices in drug-induced kidney injury assessment.
- Improved strategies can enhance decision-making and reduce attrition in drug pipelines.
More Related Videos
Related Concept Videos
Survey Safety
Kidney Structure
Sustainable Development
Household Wiring And Electrical Safety
In Vitro Drug Release Testing: Overview, Development and Validation
Electrical Current

